0001261654-26-000012
SEC filingRevenue grew 6.7% to $221.4M, but operating income fell sharply due to $11M in strategic growth expenses.
For the three months ended March 31, 2026, Universal Technical Institute reported consolidated revenue of $221.4 million, a 6.7% increase from $207.4 million in the prior-year period. The growth was primarily driven by a 7.2% rise in average full-time active students to 26,385, reflecting the impact of new campus and program launches. However, income from operations plummeted to $0.3 million from $16.9 million, a decline of 98.0%. This sharp contraction was attributed to approximately $11 million in strategic growth expenses related to new programs and campuses expected to launch over the next several years. Net income fell to $0.4 million from $11.4 million. Operating margin contracted to 0.2% from 8.1%, a decline of 790 basis points. The effective tax rate shifted to a benefit of 13.0% on pre-tax loss from an expense of 32.0% on pre-tax income.
UTI segment revenue increased 6.3% to $142.7 million, supported by a 5.3% increase in average full-time active students to 15,556. UTI operating income was $4.2 million, down from $17.7 million, as compensation and advertising costs rose significantly. Advertising expense as a percentage of revenue increased to 14.9% from 11.8%. Concorde segment revenue grew 7.5% to $78.7 million, with average full-time active students up 10.2% to 10,829. Concorde reported an operating loss of $0.2 million versus income of $3.8 million in the prior year, driven by higher compensation and advertising costs. Advertising expense as a percentage of revenue rose to 12.8% from 10.8%. The Corporate segment recorded an operating loss of $3.6 million, compared to $4.6 million in the prior year, reflecting higher compensation and general operations expenses.
Management's discussion emphasizes the execution of a three-pronged growth, diversification, and optimization strategy. Key initiatives include the opening of new campuses (UTI San Antonio in March 2026, UTI Atlanta expected summer 2026) and expansions (UTI Dallas). The company announced Phase II of its North Star strategy, including new campuses in Salt Lake City, Houston, and Atlanta, all expected to open in 2027 pending regulatory approvals. The company expects quarterly fluctuations in operating results to continue due to seasonal enrollment patterns. No specific forward guidance on revenue or earnings was provided. The company believes its cash flows from operations, cash on hand, short-term investments, and revolving credit facility will satisfy liquidity requirements for the next twelve months and beyond.
As of March 31, 2026, the company held $87.2 million in cash and cash equivalents and $74.8 million in short-term investments (classified as available-for-sale and held-to-maturity), providing substantial liquidity. Total debt stood at $131.0 million, consisting of $65.0 million drawn on the revolving credit facility, $27.0 million on the Avondale Term Loan, $35.6 million on the Lisle Term Loan, and $3.3 million in finance leases. Deferred revenue was $74.0 million, reflecting tuition received but not yet earned. The company's total assets were $852.2 million, with shareholders' equity of $339.9 million (noted in the balance sheet but not in notes; included for context).
The most significant commitment disclosed in the Notes is related to operating leases not yet commenced. As of March 31, 2026, the company has signed leases for new campus locations (UTI Salt Lake City, Concorde Atlanta, Houston, Glendale, and Burbank relocation) with total minimum lease payments of approximately $88.9 million over terms ranging from 10.5 to 15 years. These campuses are expected to open in fiscal 2027 pending regulatory approvals. Additionally, ongoing operating lease liabilities total $185.5 million (present value), with maturities through 2037. No other material purchase commitments or contractual obligations were reported.
The Notes reveal no share buyback programs or dividend activity during the period. Debt activity was significant: the company borrowed $100.0 million under its revolving credit facility and repaid $55.0 million, resulting in a net increase of $45.0 million in revolver debt. Term loan principal payments totaled approximately $0.9 million, and finance lease payments were $0.5 million. Net cash provided by financing activities was $35.9 million. Capital expenditures (from the cash flow statement) were $52.7 million for the six months, primarily for campus expansion and equipment; however, this is not detailed in the Notes.
Segment data from Note 15 shows two reportable segments: UTI and Concorde. For the six months ended March 31, 2026, UTI generated $285.6 million in revenue (up 7.5% YoY) and operating income of $20.0 million (7.0% margin). Concorde generated $156.7 million in revenue (up 9.4% YoY) and operating income of $3.6 million (2.3% margin). The improvement in Concorde's margin reflects operational leverage. Corporate expenses not allocated to segments were $7.6 million. All revenues are domestic, with no geographic breakdown provided.
Operating cash flow (CFO) of $7.1M was substantially lower than net income of $13.3M, reflecting significant working capital outflows. The primary drags were receivables ($14.2M), deferred revenue ($17.5M), and income tax payable ($8.4M), partially offset by non-cash add-backs (D&A $18.0M, stock comp $6.5M). Capex intensity rose sharply, with property and equipment purchases of $52.7M compared to $14.3M in the prior period, consuming 7.5x CFO. Free cash flow was negative as a result. Financing activities provided $35.9M, driven by $45M net proceeds from the revolving credit facility, offset by $7.7M in payroll taxes on stock compensation and $1.4M in debt repayments. No dividends or share repurchases were reported. The company also invested $53.2M in short-term investments, partially offset by $23.7M in maturities. Overall, cash generation was weak relative to earnings and investment needs, with a reliance on external financing to bridge the gap.